Paul Wu

Paul Wu is a seasoned professional in the field of biological development, currently serving as the Sr. Director of Upstream Development at Bayer Pharmaceuticals, a role they have held since 2020. With over 30 years of experience in mammalian cell culture process development, Paul has led significant initiatives, including the CMC effort for the allogeneic CAR-T program in collaboration with Atara and the process implementation for BlueRock's hESC-derived dopaminergic neurons aimed at treating Parkinson's disease. Prior to their current position, Paul was a Director at Bayer Pharmaceuticals from 2008 to 2020 and held the role of Head of Protein Isolation Development during their earlier tenure at Bayer HealthCare from 1999 to 2008. They also completed a post-doctoral fellowship at the University of Illinois-Urbana-Champaign after earning their education at Cornell University from 1986 to 1991.